Oxybutynin for Hot Flashes: Evidence, Dosing, and Safety

Oxybutynin is an anticholinergic drug, also called an antimuscarinic, first approved in the United States in 1975. It blocks acetylcholine at muscarinic receptors, which relaxes smooth muscle. In the bladder that means fewer involuntary contractions, less urgency, and fewer trips to the bathroom.

The FDA approved oxybutynin for overactive bladder, the condition marked by urinary urgency and frequency. That is its labeled use. It is sold as an immediate-release tablet, an extended-release tablet, and a skin patch and gel, and the oral versions are inexpensive generics.

Using oxybutynin for menopausal hot flashes is off-label. The FDA has not approved it for that purpose, so a clinician prescribes it based on the trial evidence and the practice guidelines rather than a label indication. Off-label prescribing is legal and common, but it is worth knowing the distinction: the hot flash use is supported by data, not by an FDA approval.

Oxybutynin is mainly used by women who cannot take estrogen or choose not to. The clearest group is breast cancer survivors. Many take tamoxifen or an aromatase inhibitor for years, both of which can trigger or worsen hot flashes, and adding estrogen is off the table.

Oxybutynin fits that situation for a specific reason: it does not interact with tamoxifen. Some other non-hormonal options do. Paroxetine, for example, blocks an enzyme that activates tamoxifen and so carries a caution for women on it. Oxybutynin has no such conflict, which is part of why it is reached for after breast cancer. The same logic applies to women who simply prefer a non-hormonal route. Our overview of non-hormonal hot flash treatment covers how the options compare, and a closer look at hot flashes when you cannot take estrogen walks through who tends to land on which drug.

The exact mechanism is not fully understood. Hot flashes start in the brain, in the part of the hypothalamus that regulates body temperature, and they end in a wave of sweating and flushing as the body tries to shed heat. Oxybutynin appears to act on both ends of that pathway.

Its anticholinergic action reduces sweating, since sweat glands are driven by acetylcholine, the same signal oxybutynin blocks. Beyond that peripheral effect, the drug is thought to act centrally on the brain's temperature control, which would explain why it lowers the number of flashes and not just the sweat. Researchers describe the central mechanism as plausible but not proven, so the honest summary is that oxybutynin works in trials while the precise reason is still being worked out.

The strongest evidence comes from the ACCRU SC-1603 trial, a randomized, double-blind, placebo-controlled study of 150 women with frequent hot flashes who were not candidates for estrogen (Leon-Ferre 2020). Two-thirds were taking tamoxifen or an aromatase inhibitor, so the trial directly tested the breast cancer setting. Women received oxybutynin 2.5 mg twice a day, 5 mg twice a day, or placebo for six weeks.

Both oxybutynin doses beat placebo. Weekly hot flash frequency fell by 7.5 episodes on the 5 mg twice-daily dose and 4.8 on the 2.5 mg twice-daily dose, compared with 2.6 on placebo. The weekly hot flash score, which weights frequency by severity, dropped by 16.9 and 10.6 on the two doses versus 5.7 on placebo. Both comparisons were statistically significant, and women on oxybutynin also reported less day-to-day interference and better quality of life. The higher dose worked better than the lower one.

An earlier randomized trial of once-daily extended-release oxybutynin reached the same conclusion in healthy postmenopausal women, cutting hot flash frequency and severity more than placebo over 12 weeks (Simon 2016). On the strength of this evidence, the Menopause Society lists oxybutynin as a recommended non-hormonal option in its 2023 position statement, graded Level I to II (NAMS 2023). The data are consistent across trials, though the studies are shorter than those behind hormone therapy.

The dose studied for hot flashes is 2.5 mg or 5 mg of immediate-release oxybutynin taken twice a day. The ACCRU trial tested both, and the 5 mg twice-daily dose gave the larger benefit while causing more dry mouth and other anticholinergic effects. Some clinicians start at the lower dose to limit side effects and step up if needed.

An extended-release tablet taken once a day has also been used and studied for hot flashes (Simon 2016). The choice between immediate-release and extended-release comes down to side effect tolerance, cost, and how a prescriber weighs the two. As with the indication itself, all of this dosing for hot flashes is off-label.

Most side effects of oxybutynin are anticholinergic and predictable. Dry mouth is the most common and the main reason people stop the drug. Others include constipation, dry eyes, blurred vision, and trouble starting urination. In the ACCRU trial these effects were more frequent on oxybutynin than placebo and were mostly mild to moderate, and they did not lead to more women dropping out (Leon-Ferre 2020). Lowering the dose usually eases them.

A separate and more serious question concerns long-term use. Large observational studies have linked higher cumulative use of anticholinergic drugs to a greater risk of dementia in older adults. A prospective study following older adults for years found that the heaviest long-term users had a higher rate of dementia than non-users (Gray 2015). This is an association, not proof that the drugs cause dementia, and it is most relevant to older adults taking strong anticholinergics over long periods. It does not mean a course of oxybutynin for hot flashes will cause dementia. It does mean the long-term anticholinergic load is worth weighing, especially in older women and in anyone already taking other anticholinergic medications, which add to the total. This trade-off is part of the decision for women weighing hot flash options after breast cancer, where treatment may run for years.

Oxybutynin is not safe for everyone. A clinician will rule it out or use extra caution in several situations:

• Untreated or narrow-angle glaucoma, which anticholinergics can worsen.
• Urinary retention or a blocked bladder outlet, since the drug can make emptying harder.
• Severe stomach or bowel motility problems, including gastric retention, because it slows the gut.
• Older age, where anticholinergic side effects and the long-term dementia signal carry more weight.
• Use of other anticholinergic drugs, which stack with oxybutynin and raise the total burden.

Anyone considering oxybutynin should give a full medication list and medical history so a clinician can check for these conflicts before prescribing.